Search

A drug was shown to improve outcomes in women with HER2-positive early breast cancer when added to standard therapy.

… Monday, June 5, 2017 Summary Women with HER2-positive breast cancer typically receive drugs that block the HER2 protein combined with chemotherapy. A large clinical trial shows that pertuzumab reduces the risk of recurrence in certain women with breast cancer. Update: On December 20, 2017 the FDA approved

Read about how Hedvig Hricak and Lawrence Dauer have been helping the National Aeronautics and Space Administration (NASA) break down an extraterrestrial "glass ceiling."

… Thursday, July 15, 2021 Hedvig Hricak and Lawrence Dauer have been helping the National Aeronautics and Space Administration (NASA) break down an extraterrestrial “glass ceiling.” The Memorial Sloan Kettering radiation experts were contributors to a https://www.nap.edu/read/26155/chapter/1 new report

Craig B. Thompson, MD, President and CEO of Memorial Sloan Kettering Cancer Center (MSK), has been named to the first City & State Life Sciences Power 50.

… Tuesday, August 3, 2021 Craig B. Thompson, MD , President and CEO of Memorial Sloan Kettering Cancer Center (MSK), has been named to the first City & State Life Sciences Power 50 . The list recognizes the most notable individuals who are making strides in the life sciences in New York, including leaders

Get helpful advice on being a caregiver for someone with cancer.

… Thursday, August 19, 2021 Cancer caregivers wear many hats: chauffer, secretary, chef, cheerleader, and more. It’s no wonder the position can feel overwhelming. “It’s a role you never applied for and probably never trained for either,” says Diane Reidy-Lagunes, a medical oncologist at Memorial Sloan

Memorial Sloan Kettering Cancer Center (MSK) has appointed Atefeh “Atti” Riazi as Chief Information Officer (CIO). In this role, Ms. Riazi will develop and implement an enterprise-wide, long-term strategic information technology (IT) plan and oversee the integration of data and technology resources across the organization.

… Thursday, January 30, 2020 Atefeh Riazi Atefeh Riazi Memorial Sloan Kettering Cancer Center (MSK) has appointed Atefeh “Atti” Riazi as Chief Information Officer (CIO), effective February 3. In this role, Ms. Riazi will develop and implement an enterprise-wide, long-term strategic information technology

Memorial Sloan Kettering Cancer Center (MSK) announces the following awards and appointments.

… Thursday, January 4, 2024 Memorial Sloan Kettering Cancer Center (MSK) announces the following awards and appointments: Omar Abdel-Wahab Received the William Dameshek Prize from the American Society of Hematology Omar Abdel-Wahab, MD , leukemia specialist, Chair of the Molecular Pharmacology at the 

Scientists are learning that — in a literal sense — metastasis is wound healing gone wrong.

… Monday, January 13, 2020 Summary Scientists at the Sloan Kettering Institute have discovered that the ability of cancers to metastasize to other organs is dependent upon their ability to coopt natural wound-healing pathways. The findings provide a new way of looking at metastasis and its possible treatment

Read about an MSK pilot study that could help patients get better sleep in the hospital overnight.

… Thursday, August 15, 2024 The constant beeping of machines. The frequent middle-of-the-night interruptions for blood draws and blood pressure checks. These are some of Luke Weber’s most vivid memories of being a 9-year-old getting treated for a rare pediatric cancer at  MSK Kids . “It felt like they

It's not only what's inside your cells that determines your cancer risk. It's what surrounds them too.

… Tuesday, June 26, 2018 Summary Scientists are learning that inflammation can play a role in cancer development. This is one example of how the environment surrounding an abnormal cell can influence its fate. Growing up, Philipp Niethammer learned from his mother to never scratch his moles. “I am not

Endometrial tumors can be reclassified into distinct subtypes based partly on their genomic makeup and may respond to targeted drugs already being tested in clinical trials, according to a large-scale genomic analysis led by researchers at Memorial Sloan Kettering Cancer Center and other centers within The Cancer Genome Atlas Research Network.

… Wednesday, May 1, 2013 Endometrial tumors can be reclassified into distinct subtypes based partly on their genomic makeup and may respond to targeted drugs already being tested in clinical trials, according to a large-scale genomic analysis led by researchers at Memorial Sloan Kettering Cancer Center